Holen Sie sich die Stockscreener-App
17.77
5.71%
0.96
Schlusskurs vom Vortag:
$16.81
Offen:
$17.7
24-Stunden-Volumen:
2.08M
Relative Volume:
3.00
Marktkapitalisierung:
$532.91M
Einnahmen:
$40.61M
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-17.63
EPS:
-1.0081
Netto-Cashflow:
$-26.70M
1W Leistung:
+28.40%
1M Leistung:
+59.66%
6M Leistung:
+30.18%
1J Leistung:
+57.96%
1-Tages-Spanne:
$16.88
$18.85
1-Wochen-Bereich:
$13.07
$18.85
52-Wochen-Spanne:
$8.27
$30.10
Clearpoint Neuro Inc Stock (CLPT) Company Profile
Firmenname
Clearpoint Neuro Inc
Sektor
Branche
Telefon
(949) 900-6833
Adresse
120 S. SIERRA AVENUE, SOLANA BEACH, CA
Compare CLPT vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLPT
Clearpoint Neuro Inc
|
17.77 | 532.91M | 40.61M | -29.07M | -26.70M | -1.0081 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Clearpoint Neuro Inc Stock (CLPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-25 | Fortgesetzt | B. Riley Securities | Buy |
| 2023-10-24 | Eingeleitet | Stifel | Buy |
| 2023-02-16 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-05 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-03-18 | Eingeleitet | Lake Street | Buy |
| 2020-07-17 | Eingeleitet | B. Riley FBR | Buy |
Alle ansehen
Clearpoint Neuro Inc Aktie (CLPT) Neueste Nachrichten
ClearPoint Neuro (CLPT) surges 26.0%: Is this an indication of further gains? - MSN
Liquidity Mapping Around (CLPT) Price Events - Stock Traders Daily
CLPT Maintained by B. Riley Securities -- Price Target Raised to $30 - GuruFocus
Clearpoint Neuro Inc (CLPT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case (NASDAQ:CLPT) - Seeking Alpha
B. Riley Adjusts ClearPoint Neuro Price Target to $30 From $20, Maintains Buy Rating - marketscreener.com
ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains? - Yahoo Finance
Clearpoint Neuro Inc (CLPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Clearpoint Neuro Inc (CLPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clearpoint Neuro Inc (CLPT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Clearpoint Neuro Inc (CLPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Clearpoint Neuro Inc (CLPT) Institutional Confidence - TradingKey
Clearpoint Neuro Inc (CLPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Clearpoint Neuro Inc (CLPT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Clearpoint Neuro Inc (CLPT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
[144] ClearPoint Neuro, Inc. SEC Filing - Stock Titan
ClearPoint Neuro (CLPT) Sees Significant Pre-Market Gains Following Partner Announcement - GuruFocus
Lake Street Maintains ClearPoint Neuro(CLPT.US) With Buy Rating - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
ClearPoint Neuro Shares Jump as FDA Progress for UniQure Therapy Highlights Platform Value - Yahoo Finance
$ClearPoint Neuro (CLPT.US)$ LG…time to see some better DDs…🏎👍🏿🔥🔥🔥🔥🔥🏁 - Moomoo
$ClearPoint Neuro (CLPT.US)$ small bag for a small pop over $20 - Moomoo
ClearPoint Neuro Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesShort-Term Outlook - newsline.com
Analysts Offer Insights on Healthcare Companies: Artivion (AORT), Incyte (INCY) and ClearPoint Neuro (CLPT) - The Globe and Mail
Stifel reiterates Clearpoint Neuro stock rating on neurosurgery platform By Investing.com - Investing.com South Africa
Stifel reiterates Clearpoint Neuro stock rating on neurosurgery platform - Investing.com
Stifel Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Maintains Target Price $16 - Moomoo
ClearPoint Neuro (CLPT) director exercises options and withholds shares for taxes - Stock Titan
Why (CLPT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint - ACCESS Newswire
Director at ClearPoint Neuro (NASDAQ: CLPT) sells shares to cover taxes - Stock Titan
Lake Street Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
CLPT: Director compensation shares (5,145) to be sold via Form 144 (06/01/2026) - Stock Titan
ClearPoint Neuro, Inc.: ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint - FinanzNachrichten.de
Director Of ClearPoint Neuro Sold 25% Of Their Shares - simplywall.st
ClearPoint Neuro plans entry into focused ultrasound market - Investing.com UK
ClearPoint Neuro plans entry into focused ultrasound market By Investing.com - Investing.com Nigeria
Understanding Momentum Shifts in (CLPT) - Stock Traders Daily
Brain ultrasound deal tests drug delivery across blood-brain barrier - Stock Titan
How The ClearPoint Neuro (CLPT) Narrative Is Shifting On Partnerships Valuation And FDA Risks - Yahoo Finance
ClearPoint Neuro (CLPT) director receives grant of 12,820 RSUs - Stock Titan
ClearPoint Neuro (CLPT) director receives 12,820 restricted stock units in equity grant - Stock Titan
[Form 4] ClearPoint Neuro, Inc. Insider Trading Activity - Stock Titan
Director at ClearPoint Neuro (CLPT) receives 12,820 restricted stock units - Stock Titan
Director at ClearPoint Neuro (NASDAQ: CLPT) awarded 12,820 RSUs - Stock Titan
Director at ClearPoint Neuro (CLPT) receives 12,820 restricted stock units grant - Stock Titan
ClearPoint Neuro | 4: Statement of changes in beneficial ownership of securities-Director FALLON LYNNETTE C - Moomoo
CLPT Q1 2026 Earnings: EPS Misses Estimates as Revenue Details Remain UndisclosedAnnual Financial Report - newsline.com
ClearPoint Neuro Shareholders Approve Incentive Plan and Directors - The Globe and Mail
ClearPoint Neuro Q1 2026 Earnings: EPS Misses Estimates Despite Positive Stock MovementPre-Earnings Setup - newsline.com
Director Matthew Klein of ClearPoint Neuro (CLPT) receives 12,417 shares from RSU vesting - Stock Titan
Finanzdaten der Clearpoint Neuro Inc-Aktie (CLPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):